间歇充气加压装置作为神经外科手术抗血栓策略:一项前瞻性随机对照试验(术后血栓栓塞事件预防试验)
本研究将283例接受择期长时间神经外科手术的患者随机分为围手术期48小时间歇充气加压装置(ICD)联合皮下低分子肝素(LMWH)组与单用LMWH组,评估静脉血栓栓塞症(VTE)预防效果。ICD+LMWH组基于临床症状的VTE发生率为2.5%、系统筛查为0%,LMWH组分别为3.1%和1.0%;校正年龄和性别后相对风险为0.7(95%CI 0.2-3.3)。作者认为围手术期在LMWH基础上加用ICD不太可能减少长时间神经外科手术的VTE事件,术前而非术后开始给予LMWH似乎有益。
要点
- 283例择期长时间神经外科手术患者随机接受ICD+LMWH或单用LMWH。
- ICD+LMWH组临床症状VTE发生率2.5%、系统筛查0%,LMWH组分别为3.1%和1.0%。
- 校正年龄和性别后VTE相对风险0.7(95%CI 0.2-3.3),作者认为加用ICD不太可能减少VTE事件。
核心结论
- 围手术期在LMWH基础上加用肢体间歇充气加压治疗,不太可能减少长时间神经外科手术的静脉血栓栓塞事件。
- 术前而非术后开始给予LMWH似乎有益。
研究设计与样本
- 前瞻性随机对照试验,纳入283例接受择期长时间神经外科手术的患者。
- 患者随机分为围手术期48小时ICD+LMWH组或单用LMWH组。
- 术后行双功超声系统筛查VTE,术后2个月评估VTE临床症状及生活质量,并评估VTE可能危险因素。
- 试验注册号:ClinicalTrials.gov NL56552.058.16。
主要发现
- ICD+LMWH组基于临床症状的VTE发生率为2.5%,基于系统筛查为0%。
- LMWH组基于临床症状的VTE发生率为3.1%(风险差-0.6%,95%CI -4.5至3.4),基于系统筛查为1.0%(风险差-1.0%,95%CI -3.0至1.0)。
- 校正年龄和性别后,ICD+LMWH组相对LMWH组的VTE相对风险为0.7(95%CI 0.2-3.3)。
临床怎么用
- 作者认为围手术期在LMWH基础上加用肢体间歇充气加压治疗不太可能减少长时间神经外科手术的VTE事件。
- 作者认为术前而非术后开始给予LMWH似乎有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative venous thrombosis is linked to high morbidity and mortality and the risk is heightened in neurosurgical patients due to prolonged immobilization, hypercoagulability, and long surgeries. Optimal prophylaxis under debate and variations in practices are prevalent. OBJECTIVE: To assess the effectiveness of limb intermittent compression devices (ICD) combined with subcutaneous low-molecular-weight heparin (LMWH) compared with LMWH alone as a prophylactic strategy for venous thromboembolism (VTE). METHODS: Patients undergoing elective lengthy neurosurgical procedures were randomized to perioperative 48-hour ICD + LMWH or to LMWH alone. Duplex ultrasonography was performed postoperatively to evaluate the presence of VTE (VTE systematic screening). Two months after surgery, clinical signs of VTE during the postoperative period were appraised (VTE clinical symptoms), and quality of life was evaluated. Possible risk factors for VTE were evaluated. RESULTS: A total of 283 patients were included in the study. The VTE incidence in the treatment arm ICD + LMWH was 2.5% based on clinical symptoms and 0% based on systematic screening, while the VTE incidence in the control arm LMWH was 3.1% (risk difference: -0.6% [95% CI, -4.5 to 3.4]) based on clinical symptoms, and 1.0% (risk difference: -1.0% [95% CI, -3.0 to 1.0]) based on systematic screening. In total, the relative risk for VTE in the ICD + LMWH treatment versus LMWH was 0.7 (95% CI, 0.2-3.3), corrected for age and sex. CONCLUSION: Limb intermittent compression therapy in addition to LMWH as antithrombotic therapy in the perioperative setting is not likely to lead to less venous thromboembolic events in lengthy neurosurgical interventions. The start of administration of LMWH preoperatively rather than postoperatively seems beneficial. TRIAL REGISTRATION: Clinical trials.gov registration number NL56552.058.16.
引用
- Zhang Z, Marcano A, Huisman MV, et al. Intermittent compression devices as antithrombotic strategy in neurosurgical interventions: a prospective randomized controlled trial (Trial In Prevention of Post-Operative ThromboEmbolic Events). J Thromb Haemost. 2025. PMID: 40288684. doi:10.1016/j.jtha.2025.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。